Giant prolactinomas: the therapeutic approach
- 11 June 2013
- journal article
- review article
- Published by Wiley in Clinical Endocrinology
- Vol. 79 (4), 447-456
- https://doi.org/10.1111/cen.12242
Abstract
Giant prolactinomas are an unusual subset of macroprolactinomas and are more commonly found in men. The goal of this review is to propose a giant prolactinoma definition and discuss the available therapeutic options for biochemical and tumour volume control. A comprehensive search of all published studies was performed between April and November 2012 in electronic databases (PubMed and Ovid). A giant prolactinoma should be defined as an adenoma with a maximum diameter of more than 4 cm that is associated with serum prolactin above 5300 mIU/l. Regarding treatment, cabergoline is the preferred dopamine agonist for medical management of giant prolactinomas because of its excellent efficacy and tolerability. Normalization of prolactin level and significant tumour reduction may be achieved in the majority of patients. Combined therapy, particularly cabergoline and surgery, may be necessary due to the large tumour load. Radiotherapy and temozolomide may be used for patients with aggressive giant prolactinomas in whom tumour volume control is not achieved with cabergoline and surgery. There is a scarcity of large studies about the management of giant prolactinoma. Cabergoline is the first-line treatment. However, caution should be exercised when comparing efficacy rates among the different treatment modalities due to the variability in study design and data quality. In this scenario, a 'standard' definition for giant prolactinomas and larger series may be helpful to assess the real efficacy and safety of each therapeutic modality.Keywords
This publication has 85 references indexed in Scilit:
- Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administrationJCI Insight, 2012
- Temozolomide in the management of dopamine agonist–resistant prolactinomasClinical Endocrinology, 2012
- Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatmentClinical Endocrinology, 2012
- Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomasSurgical Neurology International, 2012
- Obstructive Hydrocephalus, Fifth Nerve and Hypothalamus Involvement: Acute Presentation of a Giant ProlactinomaClinical Medicine Insights: Case Reports, 2012
- HER2/ErbB2 Receptor Signaling in Rat and Human Prolactinoma Cells: Strategy for Targeted Prolactinoma TherapyMolecular Endocrinology, 2011
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2010
- Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatmentActa Endocrinologica, 2009
- Efficacy and Safety of Cabergoline as First Line Treatment for Invasive Giant ProlactinomaJournal of Korean Medical Science, 2009
- A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of LactationDrug Safety, 1996